Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Gluconates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20Linked to original sources
PubMed1980

Effect of chlorhexidine gluconate on the survival of acid fast bacteria.

Mycobacterium and Nocardia species were examined for survival after exposure to chlorhexidine gluconate. In clinical samples M. smegmatis, M. phlei, M. marinum, M. gordonae, M. scrofulaceum, M. kansasii, M. chelonei complex, M. fortuitum, M. flavescens, M. avium, M. xenopi and Nocardia sp. survived pre-treatment with the agent. After exposure of saline suspensions of bacteria to chlorhexidine gluconate, M. smegmatis, M. phlei, M. marinum, M. gordonae, M. pellegrino, N. corallina, N. rubra and Rodochrous gordonae were not recovered, and M. fortuitum and N. asteroides grew poorly.

Chlorhexidine↗
PubMed1995

Effect of chlorhexidine gluconate mouth wash on the plaque microflora in children using intra oral appliances.

The effect of 0.2% chlorhexidine mouth wash (Hexidine) on the plaque microflora was evaluated on children wearing intra oral removable appliances. Plaque samples were collected from the enamel sections, both primary and permanent, mounted on the removable appliances. These appliances were worn by 12 children for one week. Plaque was allowed to accumulate on the in situ test sites and on the adjacent natural dentition. At the end of the experimental period the plaque microflora associated with the enamel sections were compared with that obtained from lingual and interproximal areas of the lower molar teeth. It was also compared with a control group of 12 children without an appliance. In addition, the effect of 0.2% chlorhexidine mouth wash on the plaque microflora for the next 14 days was also determined on both the groups. Although some quantitative difference was found between the proportion of isolates obtained from the different enamel surfaces, it was not statistically significant. There was a statistically significant increase in the isolates of plaque microflora after the insertion of removable appliance in children which decreased significantly with the use of 10 ml of 0.2% chlorhexidine gluconate mouth wash twice a day. The study indicates that the primary and permanent tooth specimens mounted on the intra-oral device collected plaque microflora similar to that present on the adjacent natural dentition and that chlorhexidine gluconate mouth wash therapy is effective in reducing plaque microflora in children with removable appliances.

Anti-Infective Agents, Local↗
PubMed1982

Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis.

Women with primary biliary cirrhosis malabsorb calcium, phosphate and vitamin D, and develop accelerated cortical bone thinning. We have assessed the value of parenteral vitamin D, oral hydroxyapatite (HA), and calcium gluconate (CG) in the treatment of cortical bone thinning in primary biliary cirrhosis. Sixty-four postmenopausal women with primary biliary cirrhosis were assigned randomly into three groups: one group receiving no mineral supplements (control), one group receiving HA, and one group receiving CG. All patients received parenteral vitamin D2 (100,000 IU monthly). Eleven patients withdrew from the study and 10 withdrew due to poor compliance (six HA, four CG). Over a 14-month follow-up period, none of the groups showed a significant change in serum calcium or inorganic phosphate levels. Pre- and posttreatment hand radiographs were used to assess changes in metacarpal cortical thickness using the technique of caliper radiogrammetry. Cortical bone loss occurred in the control group (p less than 0.01). The HA group showed a significant gain in cortical bone thickness (p less than 0.01), while no significant change occurred in the CG group. This study indicated that vitamin D2 does not halt metacarpal cortical bone thinning in primary biliary cirrhosis. The addition of CG prevents bone thinning, and HA promotes positive cortical bone balance.

Bone Diseases, Metabolic↗
PubMed1990

[Treatment of patients with postmenopausal and steroid-induced osteoporosis using sodium fluoride combined with vitamin D2 and calcium gluconate].

9 patients with postmenopausal and 5 patients with steroid-induced osteoporosis, mean age 57.9 +/- 7.76 years, were treated in the course of one year with sodium fluoride (Fluosen) in a dose of 45 mg/24 h in combination with calcium gluconate (2 g/24 h) and oil solution of vit D2 (2 mg/week). In the course of the treatment a considerable easing of the pains in the most affected parts of the skeleton was found and the height remained at the same level before and after the treatment. This correlates with the statistically significant increase of the serum levels of the total alkaline phosphatase and its bone isoenzyme by keeping a normal kalium phosphorous balance as well as with the x-ray data for retaining the bone changes liked with the osteoporosis.

Adrenal Cortex Hormones↗
PubMed1989

The influence of PTH, calcium gluconate and EDTA on the parotid saliva in the goat.

1. The role of exogenous parathyroid hormone (PTH) and stimulation or inhibition of endogenous hormone release, on the parotid gland of normal and thyroparathyroidectomized (t.x.p.t.x.) goats was studied. 2. The intravenous infusion of PTH and EDTA produced a transitory rise in saliva flow rate in intact animals. In t.x.p.t.x. goats the flow of saliva decreased transiently throughout the infusion. 3. The calcium levels in parotid saliva was unchanged throughout the infusion of PTH, EDTA, calcium gluconate both alone or with propranolol, in either intact or t.x.p.t.x. animals. 4. The parathyroid hormone infusion caused an increase in salivary phosphate concentration in both intact and operated goats. The effects of PTH upon the salivary flow and concentration of P are discussed.

Analysis of Variance↗
PubMed1986

Recurrent cutaneous leishmaniasis: successful treatment with sodium antimony gluconate.

The case of a 15-year-old boy with recurrent cutaneous leishmaniasis is reported. Species identification was based on results of serotyping and isoenzyme analysis. The patient did not respond to rifampin combined with isoniazid or to ketoconazole. Subsequent therapy with systemic sodium antimony gluconate resulted in complete regression of the lesions.

Adolescent↗
PubMed1981

[Blood mineral (Ca, Mg, Na K, Pa) levels and aspartate aminotransferase, leucine aminopeptidase, creatine phosphokinase and alkaline phosphatase activity and blood glucose levels in cattle with hypomagnesemia prior to and following infusion of a 500 ml solution containing 60 g of Mg adipate and 60 g of Ca gluconate].

The levels of various compounds in blood serum and blood plasma were tested in 14 heads of cattle with hypomagnesiaemia (x = 0.76 +/- 0.29 mg/100 ml), prior to and following infusion of 500 ml of a calcium-magnesium solution (containing 60 g of magnesium adipate and 60 g of calcium gluconate). Concomitant hypocalcaemia (6.1 mg/100 ml) was recordable only from one animal. Most of the potassium as well as all Pa and protein values in blood serum were physiologically normal, while sodium ws somewhat reduced. The glucose level in blood plasma was increased in the animal with concomitant hypocalcaemia and in one animal with poor recovery potential. The drops in magnesium and calcium levels in blood serum, following infusion, in cattle with hypomagnesiaemia was very similar to that in clinically intact cattle. Aspartate-aminotransferase and creatinine-phosphokinase activities of the serum were increased in all cattle, but leucine-aminopeptidase activity in only some of them. The activity of alkaline phosphatase of the blood serum was physiologically normal.

Adipates↗
PubMed1998

Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial.

CONTEXT: The common cold is one of the most frequently occurring illnesses and is responsible for substantial morbidity and economic loss. Biochemical evidence suggests that zinc may be an effective treatment, and zinc gluconate glycine (ZGG) lozenges have been shown to reduce the duration of cold symptoms in adults. OBJECTIVE: To determine the efficacy of ZGG treatment of colds in children and adolescents. DESIGN: A randomized, double-masked, placebo-controlled study. SETTING: Two suburban school districts in Cleveland, Ohio. PATIENTS: A total of 249 students in grades 1 through 12 were enrolled within the first 24 hours of experiencing at least 2 of 9 symptoms of the common cold. INTERVENTION: Zinc lozenges, 10 mg, orally dissolved, 5 times a day (in grades 1-6) or 6 times a day (in grades 7-12). MAIN OUTCOME MEASURES: Time to resolution of cold symptoms based on subjective daily symptom scores for cough, headache, hoarseness, muscle ache, nasal congestion, nasal drainage, scratchy throat, sore throat, and sneezing. RESULTS: Time to resolution of all cold symptoms did not differ significantly between students receiving zinc (n = 124) and those receiving placebo (n = 125) (median, 9 days; 95% confidence interval [CI], 8-9 days; median, 9 days, 95% CI, 7-10 days, respectively; P=.71). There were no significant differences in the time to resolution of any of the 9 symptoms studied. Compared with controls, more students in the zinc group reported adverse effects (88.6% vs 79.8%; P=.06); bad taste (60.2% vs 37.9%; P=.001); nausea (29.3% vs 16.1%; P=.01); mouth, tongue, or throat discomfort (36.6% vs 24.2%; P=.03); and diarrhea (10.6% vs 4.0%; P=.05). CONCLUSIONS: In this community-based, randomized controlled trial, ZGG lozenges were not effective in treating cold symptoms in children and adolescents. Further studies with virologic testing are needed to clarify what role, if any, zinc may play in treating cold symptoms.

Adolescent↗
PubMedDate not supplied

Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.

A recently marketed prolonged-release quinidine gluconate tablet was compared with the innovator's tablet in a single-dose bioavailability study with 12 healthy male subjects. The extent of absorption of quinidine from the new marketed product was only 50 per cent of the innovator's product. This finding, as well as projections of steady-state plasma concentrations to be expected during multiple-dose administration, indicated a bioequivalence problem with medically significant implications. The data obtained in this study resulted in a Class I recall of the less completely absorbed product by the U.S. Food and Drug Administration.

Adult↗
PubMed1994

Mutations affecting gluconate catabolism in Escherichia coli. Genetic mapping of loci for the low affinity transport and the thermoresistant gluconokinase.

The isolation and properties of strains of Escherichia coli carrying mutations affecting either the low affinity transport for gluconate (gene gntU) or the thermoresistant gluconokinase (gene gntK) are described. A lesion of each type was genetically characterized by transduction experiments. Both mutations mapped in the asd region, and the order was malA-glpD-asd-gntU-gntK, with the last two markers at about min 75.78 and 75.86 on the map, respectively. Mutations altering specifically gntU have not been previously reported.

Biological Transport↗
PubMed1999

Identification of a gluconic acid derivative attached to the N-terminus of histidine-tagged proteins expressed in bacteria.

Our previous studies have shown that the His tag cleaved from fusion proteins contained two distinct components P1 and P2. P1 has been identified to be a His-tagged peptide of G-H-H-H-H-H-H-H-H-H-H-S-S-G-H-I-E-G-R resulted from initiator methionine deletion, and P2 contains an unknown moiety at the second residue glycine of the tag (x-G-H-H-H-H-H-H-H-H-H-H-S-S-G-H-I-E-G-R, x = 178.0 Da). This study aimed to determine the structure of the modification by using a combination of protein isotope labeling and mass spectrometry. His-tagged FKBP was expressed in (15)N and (13)C labeling growth media respectively. Isotopic labeled His-tagged proteins ((15)N-His-FKBP and (13)C-His-FKBP) were isolated by affinity chromatography and subjected to Xa digestions to release the labeled His tag. Subsequent analyses of the released His tag by MALDI-TOF-MS indicated a mass difference of 178.0 +/- 0.2 Da, between the two (15)N-labeled peptides P1 and P2, suggesting that the modification moiety contained no nitrogen. A mass difference of 184.0 +/- 0.2 Da was observed on MALDI between (13)C-labeled peptide P1 and P2, indicating six carbons in the modification group. Also, comparing the mass shift on MALDI spectra of P1 and P2 after hydrogen/deuterium exchange revealed that the modification moiety had five hydroxyl groups. It was concluded that the modification was a gluconic acid derivative attached to the N-terminus of His-tagged proteins expressed in bacteria. The proposed structure was further confirmed by MALDI analysis of periodate oxidation products of His-tagged peptides.

Amino Acid Sequence↗
PubMedDate not supplied

Reversal of selenium and zinc deficiencies in chronic hemodialysis patients by intravenous sodium selenite and zinc gluconate supplementation. Time-course of glutathione peroxidase repletion and lipid peroxidation decrease.

In six chronic dialyzed uremic patients, an intravenous sodium selenite (Se 50 micrograms during 5 wk and then 100 micrograms) and zinc gluconate (Zn 5 mg) supplementation was performed during 20 wk at each dialysis session three times weekly. Before supplementation, plasma Se and Zn, plasma and erythrocytes (RBC) antioxidant metallo-enzymes glutathione peroxidase (GPX), and superoxide dismutase (SOD) were significantly decreased, whereas lipid peroxidation (as thiobarbituric acid reactants TBARs) was increased. To obtain a significative change in plasma selenium, we had to use an Se dose of 100 micrograms/dialysis session. Then, treatment-increased plasma Se (from 0.58 +/- 0.09 to 0.89 +/- 0.16 mumol/L) led to a repletion of RBC-GPX (from 29.6 +/- 6 to 43 +/- 5.8 U/g Hb) and increased plasma GPX levels (from 62 +/- 13 to 151 +/- 43 U/L). Plasma Zn and RBC-SOD did not vary significantly. The change of TBARs was not observed between wk 1 and 4. They decreased significantly between wk 4 (4.80 +/- 0.21 mumol/L) and wk 20 (4.16 +/- 0.26 mumol/L). We noted a low correlation between TBARs and plasma GPX. A strong correlation was observed between Se and plasma GPX. The reversal of Se deficiencies should reduce oxidative damage observed in these patients.

Aged↗
PubMedDate not supplied

Absorption and metabolism of oral zinc gluconate in humans in fasting state, during, and after a meal.

The absorption and metabolism of zinc in a commercial form for oral use (Rubozinc, 15 mg zinc as gluconate) were investigated in 10 subjects by a kinetic study of the serum zinc profile after administration of 45 mg zinc under three conditions: after an overnight fast, during a standardized breakfast, and 2 h after this meal. The pharmacokinetic parameters were calculated by a method suitable to the characterization of rebound effects (recycling of the element in the gastrointestinal tract). In fasting state, the parameters were comparable to those previously collected in the same subjects with oral 45 mg zinc as sulfate, except with very significantly higher Cmax and area under curve (AUC), showing a better bioavailability for zinc in the commercial form. The light meal perturbed the absorption process as evidenced by the significant increases in the lag time (+180%), the tmax (+57%), and the lag times for the first two cycles during the meal. However, the parameters returned to normal values 2 h after the meal. The Cmax only moderately decreased during the meal (31%) as did the AUC (-28%). An important delay in the absorption of zinc in the commercial form when taken during a meal was therefore demonstrated, but the effect on zinc bioavailability was only moderate.

Administration, Oral↗
PubMedDate not supplied

Effects of oral zinc gluconate on glucose effectiveness and insulin sensitivity in humans.

Zinc improves both insulin secretion and insulin sensitivity, and exerts insulin-like effects. We investigated its acute effects on the parameters of glucose assimilation determined with the minimal model technique from frequent sampling intravenous glucose tolerance test (FSIVGTT) in seven healthy volunteers. FSIVGTTs (0.5 g/kg of glucose, followed by 2 U insulin i.v. injection at 19 min) were performed after the subjects had taken 20 mg zinc gluconate twice (the evening before and 30 min before the beginning of the test) or placebo pills (simple blind randomized protocol). Glucose assimilation was analyzed by calculating Kg (slope of the exponential decrease in glycemia), glucose effectiveness Sg (i.e., ability of glucose itself to increase its own disposal independent of insulin response), and SI (insulin sensitivity, i.e. the effect of increases in insulinemia on glucose disposal). The two latter parameters were calculated by fitting the experimental data with the two equations of Bergman's "minimal model." Zinc increased Kg (p < 0.05) and Sg (p < 0.05), whereas SI and insulin first-phase secretion did not significantly increase. This study suggests that zinc improves glucose assimilation, as evidenced by the increase in Kg, and that this improvement results mainly from an increase in glucose effectiveness (insulin-like effect), rather than an action on insulin response or insulin sensitivity.

Administration, Oral↗
PubMedDate not supplied

99mTc-Ca-gluconate renal scintigraphy in patients with chronic renal failure.

From use of 99mTc-Ca-Sn-gluconate in patients with various degrees of renal failure the following conclusions were drawn: 1. a good relationship exists between the parenchymal and vascular patterns in scintigraphy and the functional renal impairment; 2. the morphological definition is good, since in most cases a differential diagnosis can be made between diffuse parenchymal disease and space-occupying lesions even very low glomerular filtration rate values; 3. this technique is supplementary to i.v. pyelography in patients with relatively good glomerular filtration rate values and is a reliable alternative to i.v. pyelography in those with low creatinine clearance values.

Calcium Gluconate↗
PubMed2003

The acute toxicity of gluconic acid, beta-alaninediacetic acid, diethylenetriaminepentakismethylenephosphonic acid, and nitrilotriacetic acid determined by Daphnia magna, Raphidocelis subcapitata, and Photobacterium phosphoreum.

Acute toxicity of four relatively new chelating agents and their equimolar manganese and cadmium complexes was studied. The chelating agents studied were gluconic acid (GA), beta-alaninediacetic acid (ADA), diethylenetriaminepentakismethylenephosphonic acid (DTPMP), and nitrilotriacetic acid (NTA). Three common bioassays, namely Daphnia magna, Raphidocelis subcapitata, and Photobacterium phosphoreum (Microtox bioassay) were applied. R. subcapitata proved the most sensitive to these compounds. With D. magna bioassay the LC(50) values were 600-900 mg/L with all other studied chelates and their Mn complexes, except Mn-GA, which yielded LC(50) value of 240 mg/L. The Cd-chelate complexes proved highly more toxic compared to Mn-chelate complexes or uncomplexed chelates exhibiting LC(50) values of 130-200 microg/L. However, Cd-DTPMP was an exception exhibiting LC(50) value of 2170 microg/L. That is to say, DTPMP proved the strongest chelating agent to reduce the Cd toxicity in the present study. The results from these bioassays were well in agreement to each other as well as with the results published elsewhere.

Acetic Acid↗
PubMed1997

Reversible inhibition of IK, IAHP, Ih and ICa currents by internally applied gluconate in rat hippocampal pyramidal neurones.

Previously, we reported that the spike frequency adaptation and slow afterhyperpolarizations (sAHP) in hippocampal pyramidal neurones are best preserved during whole-cell recording with a methylsulfate (MeSO4-)- based internal solution, but undergo a fast rundown when gluconate- (Gluc-)- based internal solution is used. Here we show, with internal perfusion of patch pipettes, the reversibility of the inhibitory effects of Gluc- on spike frequency adaptation and sAHP, and extend these observations to fast and medium-duration AHPs. Contrary to what might be expected based on Gluc- binding of Ca2+, the sAHP and its underlying current could be temporarily enhanced by adding 1-3 mM of the calcium chelator BAPTA to the internal solution in the presence of Gluc-. Replacement of internal MeSO4- with Gluc- did not affect the membrane resting potential or the amplitude and duration of action potentials, but reversibly increased the cell input resistance and decreased the threshold current for spike generation. Gluc- reversibly inhibited the hyperpolarization-activated non-selective cationic current (Ih), the depolarization-activated delayed rectifier K+ current (IK), the high-voltage-activated Ca2+ current and the Ca2+-activated K+ current that underlies the sAHP. The combination of these effects of Gluc- significantly alters the electrophysiological "fingerprint" of the neurone.

Animals↗